Transforming the Treatment of Hemorrhage
Cayuga Biotech is harnessing the body’s innate ability to stop bleeding with first-in-class therapeutics.
Life-threatening hemorrhage
- Hemorrhage accounts for nearly 2 million deaths per year
- Today’s treatments do not adequately treat noncompressible hemorrhage and many types of coagulation dysfunction, such as that due to Plavix® (clopidogrel), an irreversible platelet inhibitor.
- This results in delayed hemostatic control. Every second counts and can make a difference for survival.
- Hemorrhage is a top underlying cause of death after surgery, childbirth, trauma and related to the use of blood thinners.
- With over 3.5 million annual treatment opportunities, the total addressable market size is $25B.
References: Cannon 2018, Eastridge et al 2019, Gimbel et al 2018, Kelly et al 2008, ClinCalc Drug Usage Statistics 2020
Bleeding disorders
- More than 20 million people live with inherited blood or bleeding disorders.
- While tremendous progress has been made, significant unmet need remains.
- Novel mechanisms of action are needed to address gaps in current care.
References: www.pathwaytocures.org, Okaygoun et al 2021
Biomimetic Solutions for Hemorrhage Control
Cayuga was founded to address significant unmet need using proprietary science that enables us to tackle hemorrhage in a novel way.
References: Cannon 2019; Kelly et al 2008, Brohi et al 2019, Eastridge et al 2019, Clark et al 2002